Amygdala volume in depressed patients with bipolar disorder assessed using high resolution 3T MRI: The impact of medication

NeuroImage

Volumn 49, Issue 4, 2010, Pages 2966-2976

  Savitz, Jonathan ^a,f   Nugent, Allison C ^a   Bogers, Wendy ^a   Liu, Alice ^a   Sills, Rebecca ^a   Luckenbaugh, David A ^a   Bain, Earle E ^b   Price, Joseph L ^c   Zarate, Carlos ^a   Manji, Husseini K ^d   Cannon, Dara M ^a,g   Marrett, Sean ^a   Charney, Dennis S ^e   Drevets, Wayne C ^a,f  

^a NATIONAL INSTITUTE OF MENTAL HEALTH   (United States)

^b ABBOTT LABORATORIES   (United States)

^c WASHINGTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

^d JOHNSON AND JOHNSON   (United States)

^e MOUNT SINAI SCHOOL OF MEDICINE   (United States)

^f University of Oklahoma Tulsa College of Medicine   (United States)

^g NATIONAL UNIVERSITY OF IRELAND   (Ireland)

Author keywords

[No Author keywords available]

Indexed keywords

ALPRAZOLAM; AMFEBUTAMONE; AMITRIPTYLINE; CARBAMAZEPINE; CHLORPROMAZINE; CITALOPRAM; CLONAZEPAM; FLUOXETINE; GABAPENTIN; LAMOTRIGINE; LITHIUM; METHYLPHENIDATE; MOOD STABILIZER; NEFAZODONE; NORTRIPTYLINE; OLANZAPINE; PAROXETINE; PRAMIPEXOLE; PSYCHOTROPIC AGENT; RISPERIDONE; SERTRALINE; THYROXINE; TOPIRAMATE; VALPROATE SEMISODIUM; VENLAFAXINE;

ADULT; AMYGDALOID NUCLEUS; ARTICLE; BIPOLAR DISORDER; BRAIN CORTEX; BRAIN SIZE; CLINICAL ARTICLE; CONTRAST ENHANCEMENT; CONTROLLED STUDY; DEPRESSION; DRUG EFFECT; FEMALE; GRAY MATTER; HIPPOCAMPUS; HUMAN; IMAGE QUALITY; MALE; NERVE CELL PLASTICITY; NUCLEAR MAGNETIC RESONANCE IMAGING; PRIORITY JOURNAL;

ADULT; AMYGDALA; ANTIDEPRESSIVE AGENTS; BIPOLAR DISORDER; DEPRESSION; FEMALE; HUMANS; IMAGING, THREE-DIMENSIONAL; MAGNETIC RESONANCE IMAGING; MALE; MIDDLE AGED; ORGAN SIZE; PROGNOSIS; TREATMENT OUTCOME; YOUNG ADULT;

EID: 73749084524     PISSN: 10538119     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.neuroimage.2009.11.025     Document Type: Article

References (92)

1. Altshuler L.L., Bartzokis G., Grieder T., Curran J., and Mintz J. Amygdala enlargement in bipolar disorder and hippocampal reduction in schizophrenia: an MRI study demonstrating neuroanatomic specificity. Arch. Gen. Psychiatry 55 (1998) 663-664
2. Altshuler L.L., Bartzokis G., Grieder T., Curran J., Jimenez T., Leight K., Wilkins J., Gerner R., and Mintz J. An MRI study of temporal lobe structures in men with bipolar disorder or schizophrenia. Biol. Psychiatry 48 (2000) 147-162
3. Amaral D.G., and Insausti R. Hippocampal Formation. In: Paxinos G. (Ed). The Human Nervous System (1990), Harcourt, Brace, Jovanovich, San Diego, CA 711-755
4. Barnett J.H., and Smoller J.W. The genetics of bipolar disorder. Neuroscience 164 (2009) 331-343
5. Bearden C.E., Thompson P.M., Dalwani M., Hayashi K.M., Lee A.D., Nicoletti M., Trakhtenbroit M., Glahn D.C., Brambilla P., Sassi R.B., Mallinger A.G., Frank E., Kupfer D.J., and Soares J.C. Greater cortical gray matter density in lithium-treated patients with bipolar disorder. Biol. Psychiatry 62 (2007) 7-16
6. Bearden C.E., Thompson P.M., Dutton R.A., Frey B.N., Peluso M.A., Nicoletti M., Dierschke N., Hayashi K.M., Klunder A.D., Glahn D.C., Brambilla P., Sassi R.B., Mallinger A.G., and Soares J.C. Three-dimensional mapping of hippocampal anatomy in unmedicated and lithium-treated patients with bipolar disorder. Neuropsychopharmacology 33 (2008) 1229-1238
7. Behbehani M.M. Functional characteristics of the midbrain periaqueductal gray. Prog. Neurobiol. 46 (1995) 575-605
8. Bennur S., Shankaranarayana Rao B.S., Pawlak R., Strickland S., McEwen B.S., and Chattarji S. Stress-induced spine loss in the medial amygdala is mediated by tissue-plasminogen activator. Neuroscience 144 (2007) 8-16
9. Berretta S., Pantazopoulos H., and Lange N. Neuron numbers and volume of the amygdala in subjects diagnosed with bipolar disorder or schizophrenia. Biol. Psychiatry 62 (2007) 884-893
10. Beyer J.L., Kuchibhatla M., Payne M.E., Moo-Young M., Cassidy F., Macfall J., and Krishnan K.R. Hippocampal volume measurement in older adults with bipolar disorder. Am. J. Geriatr. Psychiatry 12 (2004) 613-620
11. Bezchlibnyk Y.B., Sun X., Wang J.F., Macqueen G.M., McEwen B.S., and Young L.T. Neuron somal size is decreased in the lateral amygdalar nucleus of subjects with bipolar disorder. J. Psychiatry Neurosci. 32 (2007) 203-210
12. Blumberg H.P., Kaufman J., Martin A., Whiteman R., Zhang J.H., Gore J.C., Charney D.S., Krystal J.H., and Peterson B.S. Amygdala and hippocampal volumes in adolescents and adults with bipolar disorder. Arch. Gen. Psychiatry 60 (2003) 1201-1208
13. Brambilla P., Harenski K., Nicoletti M., Sassi R.B., Mallinger A.G., Frank E., Kupfer D.J., Keshavan M.S., and Soares J.C. MRI investigation of temporal lobe structures in bipolar patients. J. Psychiatr. Res. 37 (2003) 287-295
14. Brown E.S., Woolston D.J., and Froal A.B. Amygdala volume in patients receiving chronic corticosteroid therapy. Biol. Psychiatry 63 (2007) 705-709
15. Cardinal R.N., Parkinson J.A., Hall J., and Everitt B.J. Emotion and motivation: the role of the amygdala, ventral striatum, and prefrontal cortex. Neurosci. Biobehav. Rev. 26 (2002) 321-352
16. Chang K., Karchemskiy A., Barnea-Goraly N., Garrett A., Simeonova D.I., and Reiss A. Reduced amygdalar gray matter volume in familial pediatric bipolar disorder. J. Am. Acad. Child. Adolesc. Psychiatry 44 (2005) 565-573
17. Chen G., Huang L.D., Jiang Y.M., and Manji H.K. The mood-stabilizing agent valproate inhibits the activity of glycogen synthase kinase-3. J. Neurochem. 72 (1999) 1327-1330
18. Chen G., Zeng W.Z., Yuan P.X., Huang L.D., Jiang Y.M., Zhao Z.H., and Manji H.K. The mood-stabilizing agents lithium and valproate robustly increase the levels of the neuroprotective protein bcl-2 in the CNS. J. Neurochem. 72 (1999) 879-882
19. Chen G., Rajkowska G., Du F., Seraji-Bozorgzad N., and Manji H.K. Enhancement of hippocampal neurogenesis by lithium. J. Neurochem. 75 (2000) 1729-1734
20. Chen P.S., Peng G.S., Li G., Yang S., Wu X., Wang C.C., Wilson B., Lu R.B., Gean P.W., Chuang D.M., and Hong J.S. Valproate protects dopaminergic neurons in midbrain neuron/glia cultures by stimulating the release of neurotrophic factors from astrocytes. Mol. Psychiatry 11 (2006) 1116-1125
21. Davis M., and Whalen P.J. The amygdala: vigilance and emotion. Mol. Psychiatry 6 (2001) 13-34
22. Dickstein D.P., Milham M.P., Nugent A.C., Drevets W.C., Charney D.S., Pine D.S., and Leibenluft E. Frontotemporal alterations in pediatric bipolar disorder: results of a voxel-based morphometry study. Arch. Gen. Psychiatry 62 (2005) 734-741
23. Duvernoy H.M. The Human Hippocampus (1998), Springer, Berlin
24. Feng H.L., Leng Y., Ma C.H., Zhang J., Ren M., and Chuang D.M. Combined lithium and valproate treatment delays disease onset, reduces neurological deficits and prolongs survival in an amyotrophic lateral sclerosis mouse model. Neuroscience 155 (2008) 567-572
25. First M., Spitzer R., Gibbon M., and Williams J. Structured clinical interview for DSM-IV Axis I Disorders - Patient Edition (SCID-I/P, Version 2.0) (1995), Biometrics Research Dept., New York State Psychiatric Institute
26. Foland L.C., Altshuler L.L., Sugar C.A., Lee A.D., Leow A.D., Townsend J., Narr K.L., Asuncion D.M., Toga A.W., and Thompson P.M. Increased volume of the amygdala and hippocampus in bipolar patients treated with lithium. NeuroReport 19 (2008) 221-224
27. Frangou S. The Maudsley Bipolar Disorder Project. Epilepsia 46 Suppl 4 (2005) 19-25
28. Frazier J.A., Chiu S., Breeze J.L., Makris N., Lange N., Kennedy D.N., Herbert M.R., Bent E.K., Koneru V.K., Dieterich M.E., Hodge S.M., Rauch S.L., Grant P.E., Cohen B.M., Seidman L.J., Caviness V.S., and Biederman J. Structural brain magnetic resonance imaging of limbic and thalamic volumes in pediatric bipolar disorder. Am. J. Psychiatry 162 (2005) 1256-1265
29. Frey B.N., Andreazza A.C., Cereser K.M., Martins M.R., Valvassori S.S., Reus G.Z., Quevedo J., and Kapczinski F. Effects of mood stabilizers on hippocampus BDNF levels in an animal model of mania. Life Sci. 79 (2006) 281-286
30. Glahn D.C., Bearden C.E., Caetano S., Fonseca M., Najt P., Hunter K., Pliszka S.R., Olvera R.L., and Soares J.C. Declarative memory impairment in pediatric bipolar disorder. Bipolar Disord. 7 (2005) 546-554
31. Glahn D.C., Bearden C.E., Barguil M., Barrett J., Reichenberg A., Bowden C.L., Soares J.C., and Velligan D.I. The neurocognitive signature of psychotic bipolar disorder. Biol. Psychiatry 62 (2007) 910-916
32. Gloor P., Olivier A., Quesney L.F., Andermann F., and Horowitz S. The role of the limbic system in experiential phenomena of temporal lobe epilepsy. Ann. Neurol. 12 (1982) 129-144
33. Hanaway J., Woolsey T.A., Gado M.H., and Roberts M.P. The Brain Atlas: A Visual Guide to the Human Central Nervous System (1998), Fitzgerald Science Press, Bethesda, M.D
34. Hao Y., Creson T., Zhang L., Li P., Du F., Yuan P., Gould T.D., Manji H.K., and Chen G. Mood stabilizer valproate promotes ERK pathway-dependent cortical neuronal growth and neurogenesis. J. Neurosci. 24 (2004) 6590-6599
35. Harwood A.J. Lithium and bipolar mood disorder: the inositol-depletion hypothesis revisited. Mol. Psychiatry 10 (2005) 117-126
36. Hawley C.J., Gale T.M., and Sivakumaran T. Defining remission by cut off score on the MADRS: selecting the optimal value. J. Affect. Disord. 72 (2002) 177-184
37. Johnson S.A., Wang J.F., Sun X., McEwen B.S., Chattarji S., and Young L.T. Lithium treatment prevents stress-induced dendritic remodeling in the rodent amygdala. Neuroscience 163 (2009) 34-39
38. Karl A., Schaefer M., Malta L.S., Dorfel D., Rohleder N., and Werner A. A meta-analysis of structural brain abnormalities in PTSD. Neurosci. Biobehav. Rev. 30 (2006) 1004-1031
39. Kim J.S., Chang M.Y., Yu I.T., Kim J.H., Lee S.H., Lee Y.S., and Son H. Lithium selectively increases neuronal differentiation of hippocampal neural progenitor cells both in vitro and in vivo. J. Neurochem. 89 (2004) 324-336
40. Kogelnik A.M., Loomis K., Hoegh-Petersen M., Rosso F., Hischier C., and Montoya J.G. Use of valganciclovir in patients with elevated antibody titers against Human Herpesvirus-6 (HHV-6) and Epstein-Barr Virus (EBV) who were experiencing central nervous system dysfunction including long-standing fatigue. J. Clin. Virol. 37 Suppl. 1 (2006) S33-S38
41. Ladouceur C.D., Almeida J.R., Birmaher B., Axelson D.A., Nau S., Kalas C., Monk K., Kupfer D.J., and Phillips M.L. Subcortical gray matter volume abnormalities in healthy bipolar offspring: potential neuroanatomical risk marker for bipolar disorder. J. Am. Acad. Child. Adolesc. Psychiatry 47 (2008) 532-539
42. Leventopoulos M., Ruedi-Bettschen D., Knuesel I., Feldon J., Pryce C.R., and Opacka-Juffry J. Long-term effects of early life deprivation on brain glia in Fischer rats. Brain Res. 1142 (2007) 119-126
43. Lichtenstein P., Yip B.H., Bjork C., Pawitan Y., Cannon T.D., Sullivan P.F., and Hultman C.M. Common genetic determinants of schizophrenia and bipolar disorder in Swedish families: a population-based study. Lancet 373 (2009) 234-239
44. Lyoo I.K., Kim M.J., Stoll A.L., Demopulos C.M., Parow A.M., Dager S.R., Friedman S.D., Dunner D.L., and Renshaw P.F. Frontal lobe gray matter density decreases in bipolar I disorder. Biol. Psychiatry 55 (2004) 648-651
45. Mai J.K., Assheuer J., and Paxinos G. Atlas of the Human Brain (2004), Elsevier, Amsterdam
46. Makris N., Gasic G.P., Seidman L.J., Goldstein J.M., Gastfriend D.R., Elman I., Albaugh M.D., Hodge S.M., Ziegler D.A., Sheahan F.S., Caviness Jr. V.S., Tsuang M.T., Kennedy D.N., Hyman S.E., Rosen B.R., and Breiter H.C. Decreased absolute amygdala volume in cocaine addicts. Neuron 44 (2004) 729-740
47. Manji H.K., Moore G.J., and Chen G. Clinical and preclinical evidence for the neurotrophic effects of mood stabilizers: implications for the pathophysiology and treatment of manic-depressive illness. Biol. Psychiatry 48 (2000) 740-754
48. Mark R.J., Ashford J.W., Goodman Y., and Mattson M.P. Anticonvulsants attenuate amyloid beta-peptide neurotoxicity, Ca2+ deregulation, and cytoskeletal pathology. Neurobiol. Aging 16 (1995) 187-198
49. McEwen B.S., and Olie J.P. Neurobiology of mood, anxiety, and emotions as revealed by studies of a unique antidepressant: tianeptine. Mol. Psychiatry 10 (2005) 525-537
50. McEwen B.S., Magarinos A.M., and Reagan L.P. Structural plasticity and tianeptine: cellular and molecular targets. Eur. Psychiatry 17 Suppl. 3 (2002) 318-330
51. McQuillin A., Rizig M., and Gurling H.M. A microarray gene expression study of the molecular pharmacology of lithium carbonate on mouse brain mRNA to understand the neurobiology of mood stabilization and treatment of bipolar affective disorder. Pharmacogenet. Genomics 17 (2007) 605-617
52. Merke D.P., Giedd J.N., Keil M.F., Mehlinger S.L., Wiggs E.A., Holzer S., Rawson E., Vaituzis A.C., Stratakis C.A., and Chrousos G.P. Children experience cognitive decline despite reversal of brain atrophy one year after resolution of Cushing syndrome. J. Clin. Endocrinol. Metab. 90 (2005) 2531-2536
53. Moore G.J., Bebchuk J.M., Wilds I.B., Chen G., and Manji H.K. Lithium-induced increase in human brain grey matter. Lancet 356 (2000) 1241-1242
54. Moore G.J., Cortese B.M., Glitz D.A., Zajac-Benitez C., Quiroz J.A., Uhde T.W., Drevets W.C., and Manji H.K. A longitudinal study of the effects of lithium treatment on prefrontal and subgenual prefrontal gray matter volume in treatment-responsive bipolar disorder patients. J. Clin. Psychiatry 70 (2009) 699-705
55. Moskvina V., Craddock N., Holmans P., Nikolov I., Pahwa J.S., Green E., Owen M.J., and O'Donovan M.C. Gene-wide analyses of genome-wide association data sets: evidence for multiple common risk alleles for schizophrenia and bipolar disorder and for overlap in genetic risk. Mol. Psychiatry 14 (2009) 252-260
56. Nakamura M., Salisbury D.F., Hirayasu Y., Bouix S., Pohl K.M., Yoshida T., Koo M.S., Shenton M.E., and McCarley R.W. Neocortical gray matter volume in first-episode schizophrenia and first-episode affective psychosis: a cross-sectional and longitudinal MRI study. Biol. Psychiatry 62 (2007) 773-783
57. Ongur, D., Drevets, W.C. & Price, J.L., (1998). In Neuroimage, p. A12.
58. Pearlson G.D., Barta P.E., Powers R.E., Menon R.R., Richards S.S., Aylward E.H., Federman E.B., Chase G.A., Petty R.G., and Tien A.Y. Medial and superior temporal gyral volumes and cerebral asymmetry in schizophrenia versus bipolar disorder. Biol. Psychiatry 41 (1997) 1-14
59. Pearlson G.D., Barta P.E., Powers R.E., Menon R.R., Richards S.S., Aylward E.H., Federman E.B., Chase G.A., Petty R.G., and Tien A.Y. Ziskind-Somerfeld Research Award 1996. Medial and superior temporal gyral volumes and cerebral asymmetry in schizophrenia versus bipolar disorder. Biol. Psychiatry 41 (1997) 1-14
60. Pfeifer J.C., Welge J., Strakowski S.M., Adler C.M., and DelBello M.P. Meta-analysis of amygdala volumes in children and adolescents with bipolar disorder. J. Am. Acad. Child Adolesc. Psych. 47 (2008) 1289-1298
61. Phillips M.L., Travis M.J., Fagiolini A., and Kupfer D.J. Medication effects in neuroimaging studies of bipolar disorder. Am. J. Psychiatry 165 (2008) 313-320
62. Radley J.J., and Morrison J.H. Repeated stress and structural plasticity in the brain. Ageing Res. Rev. 4 (2005) 271-287
63. Regier D.A., Farmer M.E., Rae D.S., Locke B.Z., Keith S.J., Judd L.L., and Goodwin F.K. Comorbidity of mental disorders with alcohol and other drug abuse. Results from the Epidemiologic Catchment Area (ECA) Study. JAMA 264 (1990) 2511-2518
64. Rosso I.M., Killgore W.D., Cintron C.M., Gruber S.A., Tohen M., and Yurgelun-Todd D.A. Reduced amygdala volumes in first-episode bipolar disorder and correlation with cerebral white matter. Biol. Psychiatry 61 (2007) 743-749
65. Sah P., Faber E.S., Lopez De Armentia M., and Power J. The amygdaloid complex: anatomy and physiology. Physiol. Rev. 83 (2003) 803-834
66. Sassi R.B., Nicoletti M., Brambilla P., Mallinger A.G., Frank E., Kupfer D.J., Keshavan M.S., and Soares J.C. Increased gray matter volume in lithium-treated bipolar disorder patients. Neurosci. Lett. 329 (2002) 243-245
67. Savitz J., and Drevets W.C. Bipolar and major depressive disorder: neuroimaging the developmental-degenerative divide. Neurosci. Biobehav. Rev. 33 (2009) 699-771
68. Savitz J., Solms M., and Ramesar R. Neuropsychological dysfunction in bipolar affective disorder: a critical opinion. Bipolar Disord. 7 (2005) 216-235
69. Savitz J., van der Merwe L., Stein D.J., Solms M., and Ramesar R. Neuropsychological status of bipolar I disorder: impact of psychosis. Br. J. Psychiatry 194 (2009) 243-251
70. Savitz J.B., van der Merwe L., Stein D.J., Solms M., and Ramesar R.S. Neuropsychological task performance in bipolar spectrum illness: genetics, alcohol abuse, medication and childhood trauma. Bipolar Disord. 10 (2008) 479-494
71. Senatorov V.V., Ren M., Kanai H., Wei H., and Chuang D.M. Short-term lithium treatment promotes neuronal survival and proliferation in rat striatum infused with quinolinic acid, an excitotoxic model of Huntington's disease. Mol. Psychiatry 9 (2004) 371-385
72. Singh M.K., Delbello M.P., Adler C.M., Stanford K.E., and Strakowski S.M. Neuroanatomical characterization of child offspring of bipolar parents. J. Am. Acad. Child Adolesc. Psych. 47 (2008) 526-531
73. Stewart C.A., and Reid I.C. Repeated ECS and fluoxetine administration have equivalent effects on hippocampal synaptic plasticity. Psychopharmacology (Berl.) 148 (2000) 217-223
74. Strakowski S.M., DelBello M.P., Sax K.W., Zimmerman M.E., Shear P.K., Hawkins J.M., and Larson E.R. Brain magnetic resonance imaging of structural abnormalities in bipolar disorder. Arch. Gen. Psychiatry 56 (1999) 254-260
75. Strakowski S.M., DelBello M.P., Sax K.W., Zimmerman M.E., Shear P.K., Hawkins J.M., and Larson E.R. Brain magnetic resonance imaging of structural abnormalities in bipolar disorder. Arch. Gen. Psychiatry 56 (1999) 254-260
76. Sugai F., Yamamoto Y., Miyaguchi K., Zhou Z., Sumi H., Hamasaki T., Goto M., and Sakoda S. Benefit of valproic acid in suppressing disease progression of ALS model mice. Eur. J. Neurosci. 20 (2004) 3179-3183
77. Swayze II V.W., Andreasen N.C., Alliger R.J., Yuh W.T., and Ehrhardt J.C. Subcortical and temporal structures in affective disorder and schizophrenia: a magnetic resonance imaging study. Biol. Psychiatry 31 (1992) 221-240
78. Szeszko P.R., Robinson D., Alvir J.M., Bilder R.M., Lencz T., Ashtari M., Wu H., and Bogerts B. Orbital frontal and amygdala volume reductions in obsessive-compulsive disorder. Arch. Gen. Psychiatry 56 (1999) 913-919
79. Taylor Tavares J.V., Clark L., Cannon D.M., Erickson K., Drevets W.C., and Sahakian B.J. Distinct profiles of neurocognitive function in unmedicated unipolar depression and bipolar II depression. Biol. Psychiatry 62 (2007) 917-924
80. Torrent C., Martinez-Aran A., Daban C., Sanchez-Moreno J., Comes M., Goikolea J.M., Salamero M., and Vieta E. Cognitive impairment in bipolar II disorder. Br. J. Psychiatry 189 (2006) 254-259
81. Usher J., Menzel P., Schneider-Axmann T., Kemmer C., Reith W., Falkai P., Gruber O., and Scherk H. Increased right amygdala volume in lithium-treated patients with bipolar I disorder. Acta Psychiatr. Scand. (2009)
82. Velakoulis D., Wood S.J., Wong M.T., McGorry P.D., Yung A., Phillips L., Smith D., Brewer W., Proffitt T., Desmond P., and Pantelis C. Hippocampal and amygdala volumes according to psychosis stage and diagnosis: a magnetic resonance imaging study of chronic schizophrenia, first-episode psychosis, and ultra-high-risk individuals. Arch. Gen. Psychiatry. 63 (2006) 139-149
83. Vyas A., Jadhav S., and Chattarji S. Prolonged behavioral stress enhances synaptic connectivity in the basolateral amygdala. Neuroscience 143 (2006) 387-393
84. Vyas A., Mitra R., Shankaranarayana Rao B.S., and Chattarji S. Chronic stress induces contrasting patterns of dendritic remodeling in hippocampal and amygdaloid neurons. J. Neurosci. 22 (2002) 6810-6818
85. Vyas A., Pillai A.G., and Chattarji S. Recovery after chronic stress fails to reverse amygdaloid neuronal hypertrophy and enhanced anxiety-like behavior. Neuroscience 128 (2004) 667-673
86. Wrase J., Makris N., Braus D.F., Mann K., Smolka M.N., Kennedy D.N., Caviness V.S., Hodge S.M., Tang L., Albaugh M., Ziegler D.A., Davis O.C., Kissling C., Schumann G., Breiter H.C., and Heinz A. Amygdala volume associated with alcohol abuse relapse and craving. Am. J. Psychiatry 165 (2008) 1179-1184
87. Wu X., Chen P.S., Dallas S., Wilson B., Block M.L., Wang C.C., Kinyamu H., Lu N., Gao X., Leng Y., Chuang D.M., Zhang W., Lu R.B., and Hong J.S. Histone deacetylase inhibitors up-regulate astrocyte GDNF and BDNF gene transcription and protect dopaminergic neurons. Int. J. Neuropsychopharmacol. 11 (2008) 1123-1134
88. Yasuda S., Liang M.H., Marinova Z., Yahyavi A., and Chuang D.M. The mood stabilizers lithium and valproate selectively activate the promoter IV of brain-derived neurotrophic factor in neurons. Mol. Psychiatry 14 (2009) 51-59
89. Youngs R.M., Chu M.S., Meloni E.G., Naydenov A., Carlezon Jr. W.A., and Konradi C. Lithium administration to preadolescent rats causes long-lasting increases in anxiety-like behavior and has molecular consequences. J. Neurosci. 26 (2006) 6031-6039
90. Yuan P.X., Huang L.D., Jiang Y.M., Gutkind J.S., Manji H.K., and Chen G. The mood stabilizer valproic acid activates mitogen-activated protein kinases and promotes neurite growth. J. Biol. Chem. 276 (2001) 31674-31683
91. Yucel K., Taylor V.H., McKinnon M.C., Macdonald K., Alda M., Young L.T., and MacQueen G.M. Bilateral hippocampal volume increase in patients with bipolar disorder and short-term lithium treatment. Neuropsychopharmacology 33 (2008) 361-367
92. Yucel M., Solowij N., Respondek C., Whittle S., Fornito A., Pantelis C., and Lubman D.I. Regional brain abnormalities associated with long-term heavy cannabis use. Arch. Gen. Psychiatry 65 (2008) 694-701